Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study - 13/01/26

Doi : 10.1016/S1473-3099(25)00742-X

Josefina L Razzini, MD ^a,^b,^c,^d,^{^{†
Contributed equally}}, Iago Giné-Vázquez, PhD ^a,^b,^c,^{^{†
Contributed equally}}, Jing Jin, PhD ^e,^{^{†
Contributed equally}}, María-Isolina Santiago-Pérez, BS ^f, Olaia Pérez-Martínez, MD ^f, María-Teresa Otero-Barrós, MD ^f, Nuria Suárez-Gaiche, MD ^f, Rolf Kramer, PhD ^e, Leticia Platero-Alonso, PhD ^e, Rosa-María Álvarez-Gil, MD ^g, Olga-María Ces-Ozores, RPH ^g, Victoria Nartallo-Penas, PhD ^g, Susana Mirás-Carballal, RPH ^g, Marta Piñeiro-Sotelo, RPH ^f, Juan-Manuel González-Pérez, BS ^h, Carmen Rodríguez-Tenreiro-Sánchez, PhD ^a,^b,^c, Ángela Manzanares-Casteleiro, MD ^a,^b,^c,^d, Ana Dacosta-Urbieta ^d, Cintia Álvarez-Smith, MD ^a,^b,^c,^d, Irene Rivero-Calle, MD ^a,^b,^c,^d, Antonio Salas, ProfPhD ^c,^i,^j, Carmen Durán-Parrondo, PhD ^k, Narmeen Mallah, PhD ^a,^b,^l,^m,^n,^{^{†
Contributed equally}}, Federico Martinón-Torres, ProfPhD ^a,^b,^c,^d,^{^{†
Contributed equally},}⁎

^a Genetics, Vaccines and Pediatric Infectious Diseases Research Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain

^b WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain

^c Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain

^d Translational Paediatrics and Infectious Diseases, University Hospital Complex of Santiago de Compostela and University of Santiago de Compostela, Santiago de Compostela, Spain

^e Sanofi Vaccines, Lyon, France

^f Department of Epidemiology, General Directorate of Public Health, Ministry of Health, Xunta de Galicia, Spain

^g Department of Communicable Diseases, General Directorate of Public Health, Ministry of Health, Xunta de Galicia, Galicia, Spain

^h Subdirectorate of Systems and Information Technologies, Ministry of Health, Xunta de Galicia, Galicia, Spain

ⁱ Genética de Poblaciones en Biomedicina Research Group, Health Research Institute of Santiago de Compostela, University Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain

^j Genetics Unit, Institute of Forensic Sciences, Department of Forensic Science, Faculty of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain

^k General Directorate of Public Health, Ministry of Health, Xunta de Galicia, Galicia, Spain

^l Department of Preventive Medicine, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain

^m Institute of Psychology, University of Santiago de Compostela, Santiago de Compostela, Spain

ⁿ Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain

^* Correspondence to: Prof Federico Martinón-Torres, Translational Paediatrics and Infectious Diseases, University Hospital Complex of Santiago de Compostela and University of Santiago de Compostela, Santiago de Compostela 15701, Spain Translational Paediatrics and Infectious Diseases University Hospital Complex of Santiago de Compostela and University of Santiago de Compostela Santiago de Compostela 15701 Spain

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Tuesday 13 January 2026
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Summary

Background

Real-world evidence on nirsevimab impact beyond the first season when given under universal immunisation programmes is emerging. We aimed to assess the medium-term impact of universal infant respiratory syncytial virus (RSV) prophylaxis with nirsevimab across inpatient and outpatient settings during two consecutive RSV seasons.

Methods

NIRSE-GAL is an ongoing, population-based, prospective, longitudinal study in Galicia, Spain. For this study, we included all infants eligible for nirsevimab in the 2023–24 RSV campaign in Galicia, followed up from their first RSV season (2023–24) until the end of their second RSV season (2024–25). The primary endpoint was RSV-related lower respiratory tract infection (LRTI) hospitalisation. Secondary endpoints were LRTI hospitalisation, acute bronchitis or bronchiolitis hospitalisation, pneumonia admissions, all-cause hospitalisations, and primary health-care outcomes (acute bronchitis or bronchiolitis, wheezing or asthma, LRTI, respiratory infections, acute otitis media, and all otitis diagnoses). The first recurrences of these endpoints were also assessed as secondary endpoints. Impact was estimated by Poisson regression models using weekly incidence rates of historical non-pandemic seasons (2017–18 to 2022–23) as comparators, adjusted for RSV seasonality, and evaluated across three follow-up periods: the first RSV season, the second RSV season, and up to 18 months. This study is registered with ClinicalTrials.gov , NCT06180993 .

Findings

Of 12 492 eligible infants, 11 796 received nirsevimab (94·4% coverage). Compared with historical cohorts, RSV-related LRTI hospitalisations decreased by 85·9% (95% CI 80·2–90·0) in the first season and 55·3% (22·5–74·3) in the second, with an estimated 123 infants needing to be immunised to prevent a second-season admission. First LRTI hospitalisations decreased by 59·8% (46·5–69·8) in the first season and 48·1% (33·1–59·7) up to 18 months. Acute bronchitis or bronchiolitis admissions decreased by 59·0% (37·9–72·9) in the first season and 58·7% (40·6–71·3) up to 18 months. All-cause hospitalisation declined by 20·3% (3·1–34·4) in the first season, with no significant reduction thereafter. First recurrent admissions in the second season decreased by 78·2% (25·6–93·6) for RSV-related LRTI, 62·4% (30·9–79·6) for LRTI, and 76·9% (5·3–94·4) for acute bronchitis or bronchiolitis. First outpatient visits declined during the first season by 30·8% (17·5–41·9) for bronchitis or bronchiolitis, 33·4% (21·6–43·4) for LRTI, and 27·7% (14·9–38·5) for wheezing or asthma. First recurrent outpatient visits also declined, by 52·5% (39·7–62·6) for acute bronchitis or bronchiolitis, 28·2% (17·8–37·3) for wheezing or asthma, and 47·3% (35·3–57·2) for LRTI.

Interpretation

Universal infant nirsevimab prophylaxis markedly reduced RSV-related hospitalisations and outpatient morbidity, with sustained reductions in RSV-related LRTI hospitalisations into the second season and no signal of adverse shift in RSV morbidity. These findings provide robust population-level evidence that could be valuable for infant immunisation policies and cost-effectiveness models.